Pharmaceutical News

RSS

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

A research team led by Anastassios G. Pittas, MD, MS, Endocrinologist and Co-Director of the Diabetes Center at Tufts Medical Center in Boston, has received a National Institutes of Health grant of more than $40 million over five years to conduct the Vitamin D and Type 2 diabetes study.

22 Oct 2013

Univar signs agreement with Swati Spentose to become exclusive distributor of Lidocaine products

Univar Inc., a leading global chemical distributor, announced today that it has entered into an agreement with Swati Spentose Pvt. Ltd. to become its exclusive distributor of Lidocaine products, including Lidocaine Base and Lidocaine HCl in the United States.

22 Oct 2013

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Guerbet LLC, USA -- Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).

22 Oct 2013

FDA approves Cubist Pharmaceuticals' sNDA for ENTEREG

Cubist Pharmaceuticals, Inc. today announced the approval of its supplemental new drug application (sNDA) by the U.S. Food and Drug Administration for ENTEREG (alvimopan).

21 Oct 2013

Cardiome signs agreement with Algorithm to sell, distribute BRINAVESS

Cardiome Pharma Corp. today announced that its subsidiary, Cardiome International AG, has entered into an agreement with Algorithm S.A.L., headquartered in Beirut, Lebanon, to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in certain Middle Eastern and North African countries.

21 Oct 2013

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

The District of Columbia Department of Health has released a study by the George Washington University School of Public Health and Health Services investigating prescribing of antipsychotics to District seniors.

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Adolescents vaccination for pertussis linked with lower rates of infant hospitalizations

Widespread vaccination of adolescents for pertussis was associated with lower rates of infant hospitalizations for the respiratory infection than would have been expected had teens not been inoculated according to new research in Pediatrics.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.

19 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).

19 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

Pharmaceutical News

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Parental perceptions pose major barrier to acceptance of HPV vaccination

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

Univar signs agreement with Swati Spentose to become exclusive distributor of Lidocaine products

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

FDA approves Cubist Pharmaceuticals' sNDA for ENTEREG

Cardiome signs agreement with Algorithm to sell, distribute BRINAVESS

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

New investigational drug offers potential treatment option for lung cancer

Adolescents vaccination for pertussis linked with lower rates of infant hospitalizations

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News